Journal article
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.
Boris Waldman, Jean-Claude Ansquer, David R Sullivan, Alicia J Jenkins, Neil McGill, Luke Buizen, Timothy ME Davis, James D Best, Liping Li, Michael D Feher, Christelle Foucher, Y Antero Kesaniemi, Jeffrey Flack, Michael C d'Emden, Russell S Scott, John Hedley, Val Gebski, Anthony C Keech, undefined FIELD investigators
The Lancet Diabetes & Endocrinology | Published : 2018
Abstract
BACKGROUND: Gout is a painful disorder and is common in type 2 diabetes. Fenofibrate lowers uric acid and reduces gout attacks in small, short-term studies. Whether fenofibrate produces sustained reductions in uric acid and gout attacks is unknown. METHODS: In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, participants aged 50-75 years with type 2 diabetes were randomly assigned to receive either co-micronised fenofibrate 200 mg once per day or matching placebo for a median of 5 years follow-up. We did a post-hoc analysis of recorded on-study gout attacks and plasma uric acid concentrations according to treatment allocation. The outcomes of this analysis were chan..
View full abstract